Endocrinology and Metabolism

Eui Dal Jung (Jung ED)

12 Articles

Thyroid
A Calcitonin-Negative Neuroendocrine Tumor Derived from Follicular Lesions of the Thyroid: Ga Young Kim, Chul Yun Park, Chang Ho Cho, June Sik Park, Eui Dal Jung, Eon Ju Jeon; Endocrinol Metab. 2015;30(2):221-225. Published online December 9, 2014; DOI: https://doi.org/10.3803/EnM.2015.30.2.221

4,629 View
39 Download
7 Web of Science
9 Crossref

Neuroendocrine lesions of the thyroid are rare. The most common types are medullary thyroid carcinomas (MTCs) and C-cell hyperplasia. MTCs originate from thyroid parafollicular cells that secrete calcitonin which serves as a serum marker of MTCs. Here, the rare case of a calcitonin-negative neuroendocrine tumor (NET) derived from follicular lesions of the thyroid is described. A 34-year-old man presented at our hospital for the surgical management of an incidental thyroid nodule that was observed on an ultrasound sonography (USG) of the neck. Initially, USG-guided aspiration cytology was performed, and a MTC was suspected. The expressions of thyroglobulin and thyroid transcription factor-1, which are thyroid follicular cell markers, and synaptophysin and chromogranin A, which are neuroendocrine markers, was confirmed following surgical pathology. However, the staining of calcitonin, a marker of MTCs, was not observed. A nonmedullary NET of the thyroid is uncommon, and the distinction between calcitonin-negative NETs and MTCs of the thyroid may be important due to differences in their clinical courses and management.

Citations

Citations to this article as recorded by

Medullary thyroid carcinoma with ACHT-dependent Cushing's syndrome: Therapeutic possibilities
Dušan Ilić, Sanja Ognjanović, Bojana Popović, Valentina Elezović-Kovačević, Milica Opalić-Palibrk, Lena Radić, Katarina Krstić, Đuro Macut
Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma.2024; 29(93): 46. CrossRef
Calcitonin-Negative Neuroendocrine Carcinoma of the Thyroid Gland: Case Report and Literature Review
Ricardo Fernández-Ferreira, Ildefonso Roberto De la Peña-López, Karla Walkiria Zamudio-Coronado, Luis Antonio Delgado-Soler, María Eugenia Torres-Pérez, Christianne Bourlón-de los Ríos, Rubén Cortés-González
Case Reports in Oncology.2021; 14(1): 112. CrossRef
Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature
Huai-Jie Cai, Han Wang, Nan Cao, Bin Huang, Fan-Lei Kong, Li-Ren Lu, Ya-Yuan Huang, Wei Wang
World Journal of Clinical Cases.2020; 8(1): 179. CrossRef
Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review
Claudio Gambardella, Chiara Offi, Guglielmo Clarizia, Roberto Maria Romano, Immacolata Cozzolino, Marco Montella, Rosa Maria Di Crescenzo, Massimo Mascolo, Angelo Cangiano, Sergio Di Martino, Giancarlo Candela, Giovanni Docimo
BMC Endocrine Disorders.2019;[Epub] CrossRef
Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Claudio Gambardella, Chiara Offi, Renato Patrone, Guglielmo Clarizia, Claudio Mauriello, Ernesto Tartaglia, Francesco Di Capua, Sergio Di Martino, Roberto Maria Romano, Lorenzo Fiore, Alessandra Conzo, Giovanni Conzo, Giovanni Docimo
BMC Endocrine Disorders.2019;[Epub] CrossRef
Calcitonin-Negative Neuroendocrine Tumor of the Thyroid
Megan Parmer, Stacey Milan, Alireza Torabi
International Journal of Surgical Pathology.2017; 25(2): 191. CrossRef
Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin
Qiufeng Zhou, Shuanglei Yue, Ye Cheng, Ju Jin, Haimiao Xu
Experimental and Toxicologic Pathology.2017; 69(8): 575. CrossRef
Primary Calcitonin-negative Neuroendocrine Tumor
Sabri Özden, Aysel Colak, Baris Saylam, Ömer Cengiz
World Journal of Endocrine Surgery.2017; 9(3): 104. CrossRef
LONG-TERM RESULTS OF SURGICAL TREATMENT OF PATIENTS WITH FOLLICULAR TUMORS OF THE THYROID
I. N. Zubarovskiy, M. V. Mikhailova, S. K. Osipenko
Grekov's Bulletin of Surgery.2015; 174(5): 32. CrossRef

Thyroid
Response: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.): Eon Ju Jeon, Eui Dal Jung; Endocrinol Metab. 2014;29(2):208-209. Published online June 26, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.2.208

3,374 View
22 Download

PDF PubReader

Thyroid
Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation: Eon Ju Jeon, Eui Dal Jung; Endocrinol Metab. 2014;29(1):33-39. Published online March 14, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.1.33

5,345 View
35 Download
10 Web of Science
9 Crossref

Abstract PDF PubReader

Background

A diagnostic whole-body scan (WBS) is recommended 6 to 12 months after total thyroidectomy and radioactive iodide ablation in intermediate- or high-risk patients with differentiated thyroid cancer (DTC). The aim of this study was to evaluate the necessity of a diagnostic WBS after radioactive iodide ablation in intermediate-risk patients with DTC.

Methods

A total of 438 subjects were included in the study: 183 low-risk subjects and 255 intermediate-risk subjects according to the American Thyroid Association guideline. All subjects diagnosed with DTC received 1,100 MBq (30 mCi) activity of radioiodine (I-131) following total thyroidectomy. On follow-up, all subjects underwent a diagnostic I-131 WBS after thyroid hormone withdrawal.

Results

After initial radioactive iodide ablation, 95.1% of low-risk patients and 91.4% of intermediate-risk patients showed no uptake on diagnostic WBS (P=0.135). Intermediate-risk patients with stimulated thyroglobulin (Tg) levels higher than 2.0 ng/mL showed a greater rate of radioactive iodine uptake on diagnostic WBS. Four intermediate-risk patients showed recurrence during the 16 to 80 months follow-up period. Three of the four patients with recurrence showed no uptake on diagnostic WBS and had a stimulated Tg level less than 2.0 ng/mL.

Conclusion

A diagnostic I-131 WBS after radioactive iodide ablation in intermediate-risk patients with DTC may not be necessary. A large prospective study is necessary to determine the necessity of diagnostic WBS in intermediate-risk patients with DTC.

Citations

Citations to this article as recorded by

Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer
Michele Klain, Emilia Zampella, Leandra Piscopo, Fabio Volpe, Mariarosaria Manganelli, Stefania Masone, Leonardo Pace, Domenico Salvatore, Martin Schlumberger, Alberto Cuocolo
Cancers.2021; 13(17): 4338. CrossRef
Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting
Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Suyeon Park, Mijin Kim, Tae Yong Kim, Minkyu Han, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
Annals of Surgical Oncology.2017; 24(9): 2596. CrossRef
Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients
Jose Manuel Gonzalez Carvalho, Dennis Görlich, Otmar Schober, Christian Wenning, Burkhard Riemann, Frederik Anton Verburg, Alexis Vrachimis
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(5): 744. CrossRef
Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial
Yuan Qu, Rui Huang, Lin Li
Annals of Nuclear Medicine.2017; 31(1): 71. CrossRef
ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach
Livia Lamartina, Désirée Deandreis, Cosimo Durante, Sebastiano Filetti
European Journal of Endocrinology.2016; 175(5): R185. CrossRef
The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative 131I dose over 37 GBq
Ah Reum Khang, Sun Wook Cho, Hoon Sung Choi, Hwa Young Ahn, Won Sang Yoo, Kyung Won Kim, Keon Wook Kang, Ka Hee Yi, Do Joon Park, Dong Soon Lee, June‐Key Chung, Bo Youn Cho, Young Joo Park
Clinical Endocrinology.2015; 83(1): 117. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470. CrossRef
Letter: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)
Chan-Hee Jung
Endocrinology and Metabolism.2014; 29(2): 206. CrossRef

A Case of Dopamine-Secreting Pheochromocytoma.: Jung Kyu Park, Hoon Kyu Oh, Moo Hyun Shon, Hyun Hee Kim, Eon Ju Jeon, Eui Dal Jung; Endocrinol Metab. 2012;27(2):159-162. Published online June 20, 2012; DOI: https://doi.org/10.3803/EnM.2012.27.2.159

66,416 View
41 Download
1 Crossref

Abstract PDF

A pheochromocytoma is a neuroectodermal tumor that originates from the chromaffin cells of the sympathetic system. It has typical symptoms or signs, such as periodic attacks of paroxysmal hypertension, palpitation, headache, and sweating, related to an increased catecholamine secretion. Types of catecholamine secreted from tumors are usually norepinephrine and epinerphrine. There are a few reports of dopamine-secreting pheochromocytoma with absence of other catecholamines secretion. Here, we report the case of a 59-year-old man with dopamine-secreting pheochromocytoma, with no typical symptoms or signs.

Citations

Citations to this article as recorded by

Metanephrine negative pheochromocytoma: a rare case report of dopamine-secreting tumor in an adolescent neurofibromatosis type 1 patient
Mi-Seon Lee, Rosie Lee, Sook-Hyun Park, Soon Hak Kwon, Jin-Young Park, Sang-Woo Lee, So-Mi Lee, Jung-Eun Moon
Annals of Pediatric Endocrinology & Metabolism.2023; 28(4): 302. CrossRef

Association between Serum Thyroid Stimulating Hormone Level and Papillary Thyroid Microcarcinoma in Korean Euthyroid Patients.: Hyun Sook Kim, Seung Joon Lee, Jung Kyu Park, Chang Ho Jo, Ho Sang Shon, Eui Dal Jung; Endocrinol Metab. 2011;26(4):297-302. Published online December 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.4.297

2,479 View
26 Download
1 Crossref

Abstract PDF

BACKGROUND
Thyroid cancer is a common disease and its prevalence is increasing. Recent reports have shown that an elevated thyrotropin (thyroid stimulating hormone, TSH) level is associated with thyroid cancer risk. However, the association between TSH level and thyroid cancer risk is not yet known for euthyroid patients diagnosed with papillary thyroid microcarcinoma (PTMC). METHODS: Our study included 425 patients who underwent thyroid surgery and were diagnosed with PTMC between 2008 and 2009. Control group patients were diagnosed with benign nodules < or = 1 cm in size by US-guided fine needle aspiration. Nodules with one or more suspected malignant-ultrasonographic feature(s) were excluded from this study. Patients who were not euthyroid or who took thyroid medication were also excluded. RESULTS: The mean age of all patients was 48.5 +/- 11.0 years and 88.8% were women. The mean age of those with PTMC was significantly lower than that of the control group. The mean TSH level was 1.78 +/- 0.93 mIU/L, and the mean free T4 level was 15.96 +/- 2.32 pmol/L. There was no difference in TSH level between the PTMC and control groups (1.77 +/- 0.93 mIU/L vs. 1.79 +/- 0.91 mIU/L, P = 0.829). After adjusting for age, TSH level was not correlated with tumor size (r = 0.02, P = 0.678) in the PTMC group. Moreover, the TSH level did not differ between patients with stage I and stage III-IV carcinoma (stage I, 1.77 +/- 0.95 mIU/L; stage III-IV, 1.79 +/- 0.87 mIU/L; P = 0.856). CONCLUSION: TSH levels are not elevated in euthyroid PTMC patients. Thus, further evaluation is needed before serum TSH can be used as a tumor marker for small nodules < or = 1 cm in size in euthyroid patients.

Citations

Citations to this article as recorded by

Evaluation of serum thyroid‐stimulating hormone as indicator for fine‐needle aspiration in patients with thyroid nodules
Ji Soo Choi, Chung Mo Nam, Eun‐Kyung Kim, Hee Jung Moon, Kyung Hwa Han, Jin Young Kwak
Head & Neck.2015; 37(4): 498. CrossRef

Letter: Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hurthle Cell Neoplasm and the Risk of Malignancy.: Eui Dal Jung; Endocrinol Metab. 2011;26(3):276. Published online September 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.3.276

1,612 View
18 Download

Abstract PDF: No abstract available.

A Case of Pheochromocytoma Presenting as Syncope Due to Orthostatic Hypotension.: Ji Yeun Kim, Sung Woo Kim, Seung Jun Lee, Hyun Sook Kim, Eui Dal Jung, Yun Seop Kum; Endocrinol Metab. 2011;26(2):155-159. Published online June 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.2.155

2,242 View
29 Download

Abstract PDF: Patients with pheochromocytoma manifest with headache, perspiration, and palpitation. Although most patients have either sustained or paroxysmal hypertension, some patients present with hypotension. However, severe orthostatic hypotension is relatively rare in patients with pheochromocytoma. We report here on a 72-year-old woman with pheochromocytoma and she presented with recurrent syncope due to hypotension and blood pressure fluctuation. Syncope due to hypotension is unusual in patients with pheochromocytoma and only a few such cases have been reported. The present case serves to illustrate an unexpected presentation of this tumor.

A Case of Familial Isolated Primary Hyperparathyroidism with a Novel Gene Mutation.: Sung Woo Kim, Seung Jun Lee, Hyun Suk Kim, Ji Youn Kim, Eui Dal Jung, Duk Su Jung; Endocrinol Metab. 2010;25(4):374-377. Published online December 1, 2010; DOI: https://doi.org/10.3803/EnM.2010.25.4.374

1,939 View
26 Download

Abstract PDF: Familial isolated primary hyperparathyroidism (FIHP) is an autosomal dominant disorder that is characterized by an early stage of either multiple endocrine neoplasia type 1 (MEN1) or hyperparathyroidism-jaw tumor (HPT-JT) syndrome. We report here on a case of a 42-years old woman who was diagnosed with papillary thyroid cancer and primary hyperparathyroidism. Her younger brother also had primary hyperparathyroidism. On the genetic analysis, they were both proven to have a novel frameshift mutation in the MEN1 gene (exon 10).

Free T4 is Negatively Correlated with Non-alcoholic Fatty Liver Disease in Euthyroid Women.: Eon Ju Jun, Hyun Sook Kim, Hyue Kyung Chung, Ji Hyun Lee, Sae Rom Kim, Eui Dal Jung; J Korean Endocr Soc. 2009;24(2):87-92. Published online June 1, 2009; DOI: https://doi.org/10.3803/jkes.2009.24.2.87

2,197 View
20 Download

Abstract PDF: BACKGROUND
Thyroid hormones play an important role in the regulation of lipid and carbohydrate metabolism and the body mass index (BMI), which all affect non-alcoholic fatty liver disease (NAFLD). In a previous study, we demonstrated that free T4 was negatively associated with the BMI in euthyroid women. However, there is still uncertain as to whether the thyroid function within the normal range is associated with NAFLD and liver function abnormalities. We sought to evaluate the thyroid function (free T4, TSH) and its possible relationship with NAFLD in euthyroid women. METHODS: A total of 835 euthyroid, non heavy alcoholics women who visited the Daegu Catholic University University Medical Centre for primary health screening from January 1, 2006 to December 31, 2006 participated in this cross-sectional study. The women who were not euthyroid or heavy alcoholics (> 70 g/week in women according to the DSM-IV), there was no known history of diabetes mellitus, the fasting blood glucose was more than 5.55 mmol/L and those who had viral hepatitis were excluded. Hepatic ultrasonography scanning was performed in all the participants by a single experienced radiologist. The TSH, free T4, BP, fasting glucose, serum liver enzymes (AST, ALT, GGT, T-bilirubin), lipid profiles [total-cholesterol, triglyceride (TG), HDL-C, LDL-C] and NAFLD were evaluated. RESULTS: Euthyroid women with NAFLD had lower free T4 levels than did the euthyroid women without NAFLD. After adjustment for age and BMI, free T4 was negatively correlated with TG, but free T4 was positively correlated with the total serum bilirubin. Free T4 was not correlated with the serum AST, ALT and GGT. After adjustment for age, the BMI, the fasting glucose, the GGT and free T4, but not TSH, were significantly negatively correlated with NAFLD. CONCLUSION: We demonstrated a negative correlation between free T4 and NAFLD in euthyroid women. This finding suggests lower levels of free T4 is associated with NAFLD in euthyroid subjects.

A Case of Idiopathic Central Diabetes Insipidus together with Primary Empty Sella and Combined Pituitary Hormone Deficiency.: Sun Young Ahn, Kyu Hwan Bae, Myung Hwan Kim, Ji Hyun Lee, Ho Sang Shon, Eui Dal Jung; J Korean Endocr Soc. 2007;22(4):272-276. Published online August 1, 2007; DOI: https://doi.org/10.3803/jkes.2007.22.4.272

2,262 View
38 Download

Abstract PDF: Central diabetes insipidus is a heterogeneous condition that is characterized by polyuria and polydipsia, and this is due to a deficiency of arginine vasopressin. Central diabetes insipidus is rare in children and young adults, and up to 50 percent of cases are idiopathic. Genetic abnormalities in the homeobox genes have recently been shown, on sellar magnetic resonance imaging, to be associated with combined pituitary hormone deficiency with pituitary defect. We report here on a 44-year-old female who suffered from polydipsia, polyuria and primary amenorrhea since childhood. She was diagnosed with idiopathic central diabetes insipidus together with primary empty sella and combined pituitary hormone deficiency. On the genetic analysis, she was proven to have a point mutation of the PROP-1 gene, which is known as a cause of combined pituitary hormone deficiency.

Galectin-3 and Thyroid Peroxidase Expression in Thyroid Nodules.: Gyu Hwan Bae, Hyun Dae Yoon, Jong Yup Bae, Ho Sang Son, Eui Dal Jung, Sung Pyo Hong, Myung Hwan Kim, Sun Ah Lee, Hyun Sook Kim, Sun Young Ahn; J Korean Endocr Soc. 2007;22(2):105-111. Published online April 1, 2007; DOI: https://doi.org/10.3803/jkes.2007.22.2.105

2,354 View
22 Download
2 Crossref

Abstract PDF

BACKGROUND
The accurate diagnosis of a thyroid nodule is important in deciding a patient's treatment plan and for predicting the prognosis. The histopathological diagnosis of resected specimens are largely positively accomplished, but the consistency of the diagnosis is low when the specimen shows a small carcinomatous cytological feature or the nodule does not express papillary proliferation. Therefore, the need for supplementary diagnostic measures is increased. Herein, the expressions of galectin-3 and thyroid peroxidase (TPO) of resected specimens were investigated using immunohistochemical staining, and their potential for contributing to an accurate diagnosis studied. METHODS: The specimens included 195 resected thyroid nodules obtained from 179 patients having undergone thyroid surgery. Immunohistochemical staining for two useful antibodies, galectin-3 and TPO, were performed, and the expressions of these two antibodies investigated with regard to the histological diagnosis. RESULTS: The sensitivity, specificity, and positive and negative predictive values of galectin-3 and TPO for detecting papillary carcinomas were all 100%, but these values were low for other forms of carcinoma. CONCLUSION: Our data showed the diagnosis of thyroid nodules, using immunohistochemical staining for galectin-3 and TPO, was very useful for detecting thyroid papillary carcinoma, but insufficiently sensitive for follicular carcinoma. Immunohistochemical staining for TPO is also useful for distinguishing cases when a false positive result for galectin-3 is obtained.

Citations

Citations to this article as recorded by

Immunohistochemical Expression of CXC Chemokine Receptor 4 and Galectin-3 in Follicular Tumors of Thyroid
Ji Eun Park, Bu Kyung Kim, Sangeon Gwoo, Yo-Han Park, Young Sik Choi, Young Ok Kim
Journal of Korean Thyroid Association.2012; 5(1): 45. CrossRef
The Significance of Immunohistochemical Staining in Thyroid Nodule: TPO and Galectin-3
G Gong
Journal of Korean Endocrine Society.2007; 22(2): 95. CrossRef

Urinary Bladder Pheochromocytoma with a Long Asymptomatic Period.: Soon Hong Park, Jung Eun Lee, Sung Soo Moon, Joo Young Lee, Eui Dal Jung, Jung Guk Kim, In Kyu Lee, Bo Wan Kim; J Korean Endocr Soc. 2006;21(5):402-407. Published online October 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.5.402

1,814 View
20 Download

Abstract PDF: Pheochromocytoma arises from chromaffin cells of the paraganglionic system. Urinary bladder pheochromocytoma is very rare tumor that accounts for less than 0.06% of all urinary bladder tumors and it is less than 1% of all pheochromocytoma. Urinary bladder pheochromocytoma usually arises from the sympathetic nervous system of the bladder wall. Paroxysmal headache and palpitation precipitated by micturition are common specific symptoms of this tumor. The paroxysm commonly persists or the patients relapse in a few days or months. Herein, we report a case of urinary bladder pheochromocytoma with a long asymptomatic period.

Author index